Stéphane Oudard1, Igor Latorzeff2, Armelle Caty3, Laurent Miglianico4, Emmanuel Sevin5, Anne Claire Hardy-Bessard6, Remy Delva7, Frédéric Rolland8, Loic Mouret9, Franck Priou10, Philippe Beuzeboc11, Gwenaelle Gravis12, Claude Linassier13, Philippe Gomez14, Eric Voog15, Xavier Muracciole16, Christine Abraham17, Eugeniu Banu18, Jean-Marc Ferrero19, Alain Ravaud20, Ivan Krakowski21, Jean-Léon Lagrange22, Gaël Deplanque23, David Zylberait24, Laurence Bozec25, Nadine Houede26, Stéphane Culine27, Reza Elaidi28. 1. Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France. 2. Department of Oncology Radiotherapy, Clinique Pasteur, Toulouse, France. 3. Department of Medical Oncology, Centre Galilée, Hôpital Privé la Louvière, Lille, France. 4. Department of Oncology Radiotherapy, Centre Hospitalier Privé St Grégoire, Rennes, France. 5. Department of Medical Oncology, Centre François Baclesse, Caen, France. 6. Department of Medical Oncology, Hôpital Privé des Côtes d'Armor, Plérin, France. 7. Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France. 8. Department of Medical Oncology, Institut de Cancérologie de l'Ouest, St Herblain, France. 9. Department of Medical Oncology, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France. 10. Department of Medical Oncology, Centre Hospitalier de Vendée, La Roche sur Yon, France. 11. Department of Medical Oncology, Institut Curie, Paris, France. 12. Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France. 13. Department of Medical Oncology, Centre Hospitalier Bretonneau, Tours, France. 14. Department of Oncology Radiotherapy, Centre Joliot Curie, Rouen, France. 15. Department of Medical Oncology, Clinique Victor Hugo, Institut Inter-régional de Cancérologie, Le Mans, France. 16. Department of Oncology Radiotherapy, Hôpital de la Timone, Marseille, France. 17. Department of Medical Oncology, Centre Hospitalier Versailles André Mignot, Le Chesnay, France. 18. Department of Medical Oncology, Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania. 19. Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France. 20. Department of Medical Oncology, Hôpital St Andre, Bordeaux, France. 21. Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre Les Nancy, France. 22. Department of Medical Oncology, Hôpital Henri Mondor, Creteil, France. 23. Department of Medical Oncology, Fondation Hopital St Joseph, Paris, France. 24. Department of Medical Oncology, Centre Hospitalier de Compiegne, Compiegne, France. 25. Department of Medical Oncology, Hôpital Foch, Suresnes, France. 26. Department of Medical Oncology, Institut Bergonie, Bordeaux, France. 27. Department of Medical Oncology, Hôpital St Louis, Paris, France. 28. Association pour la Recherche sur les Thérapeutiques Innovantes en Cancérologie, Paris, France.
Abstract
IMPORTANCE: Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting. OBJECTIVE: To assess the benefit of ADT plus docetaxel in patients presenting with rising prostate-specific antigen (PSA) levels after primary local therapy and high-risk factors but no evidence of metastatic disease. DESIGN, SETTING, AND PARTICIPANTS: This open-label, phase 3, randomized superiority trial comparing ADT plus docetaxel vs ADT alone enrolled patients from 28 centers in France between June 4, 2003, and September 25, 2007; final follow-up was conducted April 12, 2017, and analysis was performed May 2 to July 31, 2017. Patients had undergone primary local therapy for prostate cancer, were experiencing rising PSA levels, and were considered to be at high risk of metastatic disease. Stratification was by prior local therapy and PSA-level doubling time (≤6 vs >6 months), and intention-to-treat analysis was used. INTERVENTIONS: Patients were randomly assigned to receive ADT (1 year) plus docetaxel, 70 mg/m2 (every 3 weeks [6 cycles]), or ADT alone (1 year). MAIN OUTCOMES AND MEASURES: The primary outcome was PSA progression-free survival (PSA-PFS). Secondary end points were PSA response, radiologic PFS, overall survival, safety, and quality of life. RESULTS: Overall, 254 patients were randomized (1:1) to the trial; median age, 64 years in the ADT plus docetaxel arm, 66 years in the ADT alone arm. At a median follow-up of 30.0 months, the median PSA-PFS was 20.3 (95% CI, 19.0-21.6) months in the ADT plus docetaxel arm vs 19.3 (95% CI, 18.2-20.8) months in the ADT alone arm (hazard ratio [HR], 0.85; 95% CI, 0.62-1.16; P = .31). At a median follow-up of 10.5 years, there was no significant between-arm difference in radiologic PFS (HR, 1.03; 95% CI, 0.74-1.43; P = .88). Overall survival data were not mature. The most common grade 3 or 4 hematologic toxic effects in the ADT plus docetaxel arm were neutropenia (60 of 125 patients [48.0%]), febrile neutropenia (10 [8.0%]), and thrombocytopenia (4 [3.0%]). There was no significant between-arm difference in overall quality of life. CONCLUSIONS AND RELEVANCE: Compared with ADT alone, combined ADT plus docetaxel therapy with curative intent did not significantly improve PSA-PFS in patients with high-risk prostate cancer and rising PSA levels and no evidence of metastatic disease. TRIAL REGISTRATION: French Health Products Safety Agency identifier: 030591; ClinicalTrials.gov identifier: NCT00764166.
IMPORTANCE: Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting. OBJECTIVE: To assess the benefit of ADT plus docetaxel in patients presenting with rising prostate-specific antigen (PSA) levels after primary local therapy and high-risk factors but no evidence of metastatic disease. DESIGN, SETTING, AND PARTICIPANTS: This open-label, phase 3, randomized superiority trial comparing ADT plus docetaxel vs ADT alone enrolled patients from 28 centers in France between June 4, 2003, and September 25, 2007; final follow-up was conducted April 12, 2017, and analysis was performed May 2 to July 31, 2017. Patients had undergone primary local therapy for prostate cancer, were experiencing rising PSA levels, and were considered to be at high risk of metastatic disease. Stratification was by prior local therapy and PSA-level doubling time (≤6 vs >6 months), and intention-to-treat analysis was used. INTERVENTIONS: Patients were randomly assigned to receive ADT (1 year) plus docetaxel, 70 mg/m2 (every 3 weeks [6 cycles]), or ADT alone (1 year). MAIN OUTCOMES AND MEASURES: The primary outcome was PSA progression-free survival (PSA-PFS). Secondary end points were PSA response, radiologic PFS, overall survival, safety, and quality of life. RESULTS: Overall, 254 patients were randomized (1:1) to the trial; median age, 64 years in the ADT plus docetaxel arm, 66 years in the ADT alone arm. At a median follow-up of 30.0 months, the median PSA-PFS was 20.3 (95% CI, 19.0-21.6) months in the ADT plus docetaxel arm vs 19.3 (95% CI, 18.2-20.8) months in the ADT alone arm (hazard ratio [HR], 0.85; 95% CI, 0.62-1.16; P = .31). At a median follow-up of 10.5 years, there was no significant between-arm difference in radiologic PFS (HR, 1.03; 95% CI, 0.74-1.43; P = .88). Overall survival data were not mature. The most common grade 3 or 4 hematologic toxic effects in the ADT plus docetaxel arm were neutropenia (60 of 125 patients [48.0%]), febrile neutropenia (10 [8.0%]), and thrombocytopenia (4 [3.0%]). There was no significant between-arm difference in overall quality of life. CONCLUSIONS AND RELEVANCE: Compared with ADT alone, combined ADT plus docetaxel therapy with curative intent did not significantly improve PSA-PFS in patients with high-risk prostate cancer and rising PSA levels and no evidence of metastatic disease. TRIAL REGISTRATION: French Health Products Safety Agency identifier: 030591; ClinicalTrials.gov identifier: NCT00764166.
Authors: Emmanuel S Antonarakis; Yongmei Chen; Sally I Elsamanoudi; Stephen A Brassell; Mario V Da Rocha; Mario A Eisenberger; David G McLeod Journal: BJU Int Date: 2010-11-23 Impact factor: 5.588
Authors: Roderick C N van den Bergh; Niels J van Casteren; Thomas van den Broeck; Eve R Fordyce; William K M Gietzmann; Fiona Stewart; Steven MacLennan; Saeed Dabestani; Joaquim Bellmunt; Michel Bolla; Erik Briers; Philip Cornford; Steven Joniau; Malcolm D Mason; Vsevolod Matveev; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Thomas Wiegel; Thomas B Lam; Nicolas Mottet Journal: Eur Urol Date: 2015-12-12 Impact factor: 20.096
Authors: Susan Goodin; Patrick Medina; Terry Capanna; Weichung J Shih; Sybil Abraham; Jessica Winnie; Susan Doyle-Lindrud; Mary Todd; Robert S DiPaola Journal: J Clin Oncol Date: 2005-02-28 Impact factor: 44.544
Authors: Ping Zhou; Ming-Hui Chen; David McLeod; Peter R Carroll; Judd W Moul; Anthony V D'Amico Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: William U Shipley; Michelle Desilvio; Michael V Pilepich; Mack Roach; Harvey B Wolkov; William T Sause; Philip Rubin; Colleen A Lawton Journal: Int J Radiat Oncol Biol Phys Date: 2006-01-19 Impact factor: 7.038
Authors: Ryan M Franke; Michael A Carducci; Michelle A Rudek; Sharyn D Baker; Alex Sparreboom Journal: J Clin Oncol Date: 2010-09-20 Impact factor: 44.544
Authors: Judd W Moul; Hongyu Wu; Leon Sun; David G McLeod; Christopher Amling; Timothy Donahue; Leo Kusuda; Wade Sexton; Keith O'Reilly; Javier Hernandez; Andrew Chung; Douglas Soderdahl Journal: J Urol Date: 2004-03 Impact factor: 7.450
Authors: Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar Journal: Lancet Date: 2015-12-21 Impact factor: 79.321
Authors: Michael J Morris; Jose Mauricio Mota; Kristine Lacuna; Patrick Hilden; Martin Gleave; Michael A Carducci; Fred Saad; Erica D Cohn; Julie Filipenko; Glenn Heller; Neal Shore; Andrew J Armstrong; Howard I Scher Journal: Eur Urol Oncol Date: 2021-05-18
Authors: Hyunho Han; Hyung Ho Lee; Kwibok Choi; Young Jun Moon; Ji Eun Heo; Won Sik Ham; Won Sik Jang; Koon Ho Rha; Nam Hoon Cho; Filippo G Giancotti; Young-Deuk Choi Journal: Prostate Cancer Prostatic Dis Date: 2021-04-26 Impact factor: 5.455
Authors: Nicholas D James; Fiona C Ingleby; Noel W Clarke; Claire L Amos; Gerhardt Attard; Christopher D Brawley; Simon Chowdhury; William Cross; David P Dearnaley; Duncan C Gilbert; Silke Gillessen; Robert J Jones; Ruth E Langley; Archie Macnair; Zafar I Malik; Malcolm D Mason; David J Matheson; Robin Millman; Chris C Parker; Hannah L Rush; J Martin Russell; Carly Au; Alastair W S Ritchie; Ricardo Pereira Mestre; Imtiaz Ahmed; Alison J Birtle; Susannah J Brock; Prantik Das; Victoria A Ford; Emma K Gray; Robert J Hughes; Caroline B Manetta; Duncan B McLaren; Ashok D Nikapota; Joe M O'Sullivan; Carla Perna; Clive Peedell; Andrew S Protheroe; Santhanam Sundar; Jacob S Tanguay; Shaun P Tolan; John Wagstaff; Jan B Wallace; James P Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes Journal: JNCI Cancer Spectr Date: 2022-07-01
Authors: Megan Crumbaker; Eva K F Chan; Tingting Gong; Niall Corcoran; Weerachai Jaratlerdsiri; Ruth J Lyons; Anne-Maree Haynes; Anna A Kulidjian; Anton M F Kalsbeek; Desiree C Petersen; Phillip D Stricker; Christina A M Jamieson; Peter I Croucher; Christopher M Hovens; Anthony M Joshua; Vanessa M Hayes Journal: Cancers (Basel) Date: 2020-05-07 Impact factor: 6.639